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EXPLORING THE POTENTIAL YIELD OF PRENATAL TESTING BY EVALUATING A
POSTNATAL POPULATION WITH STRUCTURAL ABNORMALITIES
Abstract
Peyton Bree Busby, BS
Advisory Professor: Blair K. Stevens, MS, CGC

After identification of one or more structural abnormalities in a fetus, pregnant
women are offered a host of different testing options to identify a possible genetic cause
for the structural abnormality(ies). When considering what type of test to undertake,
there is limited information on the diagnostic yield of the varying testing options. Some
women may miss an opportunity to gain the information they are seeking or make a less
informed decision when they choose a testing option after identification of a structural
abnormality due to this lack of information. This study aimed to identify the potential
diagnostic yield of all currently available prenatal testing options in the presence of a
structural abnormality through a retrospective chart review of a postnatal population of
infants with structural abnormalities. Of 791 patients with at least one structural
abnormality, 691 patients underwent genetic testing and 222 had a genetic aberration
that explained their phenotype. Chromosomal microarray had the highest potential
diagnostic yield across the entire cohort and among individuals with multiple structural
abnormalities, 26.8% (95% CI: 23.5 - 30.3) and 29.0% (95% CI: 25.3 - 33.3)
respectively, which reached significance (p <0.001, p = 0.029) compared to all of the
other prenatal screening and diagnostic options. In the isolated cohort, whole exome
sequencing had a higher potential diagnostic yield of causative pathogenic aberrations,
followed by chromosome microarray. Expanded non-invasive prenatal testing (NIPT with
microdeletions and whole genome NIPT) had a higher potential yield than traditional
NIPT. Whole genome NIPT also had a comparable yield as a karyotype, although this
did not reach statistical significance. While interesting, it is important to consider the
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limited data available on expanded NIPT panels compared to the robust studies of
traditional NIPT and how this might affect these results and post-test counseling
regarding positive screening results. This study provides further evidence for the use of
chromosomal microarray for the highest potential diagnostic yield in genetic testing after
identification of one or more structural abnormalities.
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Introduction
Structural abnormalities occur in 3-5% of all pregnancies and have a wide range
of prognoses and etiologies [1]. Structural abnormalities (birth defects) are differences in
fetal development that can affect any organ in the body [1]. Understanding the etiology
of a structural abnormality allows for more accurate counseling regarding prognosis,
pregnancy and neonatal management, and recurrence risks for future children. Common
genetic etiologies include aneuploidy such as Down syndrome, copy number variants
(CNVs) such as 22q11 deletion syndrome, and single gene disorders such as Noonan
syndrome. Due to the association between genetic conditions and structural
abnormalities, women are offered a host of different genetic testing options upon
identification of an ultrasound abnormality. Testing options can include diagnostic testing
via chorionic villus sampling (CVS) or amniocentesis, or for those who decline diagnostic
testing, a variety of non-invasive prenatal testing (NIPT) options.
Diagnostic testing is clearly superior to screening tests when evaluating for
genetic abnormalities as it allows for more comprehensive and more accurate testing,
but these benefits must be weighed against procedure related risks.
When a diagnostic procedure is performed, a multitude of genetic tests can be
ordered, such as karyotype, chromosomal microarray (CMA), and next-generation
sequencing for single gene disorders. When offering prenatal testing after identification
of a structural abnormality, there is limited information available on the diagnostic yield of
each testing option to aid providers and patients in counseling and decision-making.
Benn et al. found that when the indication for prenatal testing is a structural anomaly, a
karyotype will detect an abnormality in 16.7% of pregnancies that undergo diagnostic
testing [3]. Donnelly et al. found in karyotypically normal pregnancies, chromosome
microarray detected an abnormality in an additional 5.6% of cases with one structural
anomaly and 13.0% of cases with more than one structural anomaly [4]. There have
been multiple studies (with differing inclusion criteria and testing strategies) looking at
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the potential yield of prenatal WES, producing a wide diagnostic yield range from 6.280% that generally falls within the 15-45% range [5-8]. Although these studies provide
some information about the yield of diagnostic testing options, many are limited
regarding the specific type of structural abnormality, and do not include any comparison
to the rapidly expanding NIPT options [5] [9].
The detection rate of NIPT for common aneuploidies (13, 18, 21, X, and Y) range
between 91.7%-99.9% [11]. In addition to common aneuploidy, expanded NIPT panels
are currently clinically available that include options such as screening for other
chromosome aneuploidies, select microdeletions, genome-wide deletions or duplications
greater than 7Mb and certain autosomal dominant single gene disorders [12-14]. The
detection rates for these additional conditions are lower, ranging between 60-85% for
specific CNVs and 43-99% for select single gene disorders [12-14]. However, peerreviewed publications on the accuracy of NIPT for CNVs and single gene disorders is
limited and peer reviewed data has yet to be published.
Many studies on expanded NIPT (NIPT for common microdeletions, whole
genome NIPT, and NIPT for single gene disorders) do not have outcome data for all
pregnancies tested, and often have a small number of positive results with multiple false
positives [13-17]. This leads to vastly different quoted detection rates and confidence
intervals for conditions within a specific tests and across different testing platforms [1217].
Screening tests such as NIPT are desirable to patients because they do not pose
a risk for miscarriage to the pregnancy, but they are not diagnostic and only screen for a
limited number of conditions. Therefore, the American College of Obstetrics and
Gynecology does not recommend the use of cell-free fetal DNA screening tests after the
identification of a structural abnormality on ultrasound [18].
Despite these recommendations, many women decline diagnostic testing and opt
for NIPT. Since the introduction of NIPT, the rate of invasive testing for all indications
2

has decreased significantly, by as much as 53% and 77% for amniocentesis and CVS
respectively [19]. The rate of invasive testing is predicted to continue to decline by as
much as 91% as predicted by some models [20]. Many women indicate their choice of
NIPT is influenced by its high detection rates [21]. However, data has shown that
patients overestimate the accuracy of NIPT for Down syndrome and overestimate the
number of conditions NIPT can screen for [22]. It is also unclear if women who have a
fetus with a structural abnormality also use this same reasoning when electing NIPT, as
there have not been extensive studies in this particular patient population.
Few studies have evaluated the utility of NIPT in the presence of congenital
anomalies. One retrospective study evaluated 251 pregnancies with NIPT results and
abnormal ultrasound findings, including multiple anomalies, isolated anomalies,
increased nuchal translucency (>3.5mm), soft markers, and growth restriction [23]. NIPT
identified 26 genetic aberrations in this population. Thirty three of the 224 patients with
negative NIPT underwent diagnostic testing postnatally, which identified an additional 7
aberrations missed by NIPT [23]. Over half of the study population had increased nuchal
translucency and soft signs, which are associated mostly with aneuploidy and therefore
more likely to be detected by NIPT [23]. Another study by Sotiriadis et al. [24] evaluated
the potential yield of NIPT for common aneuploidies on prenatal CMA samples from
pregnancies identified as having one or more structural abnormalities. Only 7 of the 22
aberrations identified on CMA would have been picked up by NIPT for common
aneuploidies, and only one of the fifteen other aberrations would have potentially been
picked up by NIPT plus common microdeletions [24].
This study aims to address the gap in the literature concerning the yield of
prenatal testing after identification of specific structural abnormalities, particularly for
newer tests such as cell-free DNA screening for single gene disorders and diagnostic
sequencing tests. This information will allow for a better understanding of the likelihood
of detecting an underlying genetic condition or an increased risk for a condition by each
3

prenatal test and ultimately facilitate more accurate genetic counseling and more
informed decision making.

Methods
Inclusion and Exclusion Criteria
Individuals for this study were selected from a database of patients maintained
by the Division of Medical Genetics in the Department of Pediatrics at McGovern
Medical School at the University of Texas Health Science Center at Houston (UTHealth).
The database consists of patients seen by the UTHealth Medical Genetics team since
January of 2014. Protocol was submitted to the University of Texas Health Science
Center Internal Review Board and Memorial Hermann Internal Review Board and was
approved on June 12th, 2018 and September 11th, 2018 respectively (HSC-MS-18-0458).
Data from the clinical database was abstracted into a study database created in
Qualtrics (Qualtrics, Provo, UT) and exported to Stata (v13.1, College Station, TX) for
analysis.
Patients listed in the database were included in the study if, 1) they were initially
seen by the genetics team as an inpatient consult at Children’s Memorial Hermann
Hospital, in Houston, Texas, 2) initial consult occurred from January 1st, 2014 through
December 31st, 2017, 3) consulted within the first 6 months of life, 4) review of clinical
records demonstrated evidence of at least one structural abnormality potentially
detectable by ultrasound. Patients with only structural abnormalities that are not
potentially detectable by prenatal ultrasound were excluded.
Once patients in the database satisfied inclusion criteria 1-3, their inpatient and
outpatient medical records were reviewed from the corresponding electronic medical
record systems (EMR). Only patients with a structural abnormality potentially detectable
by ultrasound were included in the statistical analysis. Abnormalities not potentially
detectable by prenatal ultrasound were excluded. Data on genetic testing results was
4

obtained from both the inpatient and outpatient EMR systems. When available,
information regarding the reason for lack of testing was recorded.

Structural abnormalities
A list of structural abnormalities to be included in the analysis was generated
from a previous study comparing CMA and karyotype in the presence of structural
abnormalities [4] and from internal lists of structural abnormalities at the Children’s
Memorial Hermann Fetal Center. Structural abnormalities were determined to be either
potentially detectable by ultrasound or not by two maternal fetal medicine specialists with
a total of 37 years of experience in the field.

Determination of potential diagnostic yield of prenatal testing options
Appropriate Prenatal Test for Condition
The potential diagnostic yield of prenatal testing was determined first by
evaluating whether the genetic conditions detected in our study population could have
been detected by clinically available prenatal screening and diagnostic tests. Diagnostic
testing options included in the analysis include aneuploidy fluorescence in situ
hybridization (FISH), karyotype, chromosomal microarray (CMA), next-generation
sequencing (NGS) panels, prenatal WES, methylation studies, and trinucleotide repeat
analysis. Screening options included a variety of non-invasive prenatal testing (NIPT)
screens, which are outlined in Table 1.
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Table 1: Non-invasive prenatal screening options included in this study
Prenatal screening option

Conditions screened for

NIPT for common aneuploidies
(NIPT)

Aneuploidy for chromosomes 13, 18, and 21

NIPT + sex chromosome
abnormalities (NIPT+SCAs)

Aneuploidy for chromosomes 13, 18, 21, and X and Y

NIPT + common
microdeletions/copy number
variants (NIPT+CNVs)

Aneuploidy for chromosomes 13, 18, 21, X, and Y and
common microdeletion syndromes 22q11.2 deletion
syndrome (DiGeorge syndrome), 11q- (Jacobsen
syndrome), 5p- (Cri-du-Chat), 8q24.1- (Langer-Giedion
syndrome), 1p36 deletion syndrome, 4p- (WolfHirschhorn syndrome),15q- (Prader-Willi syndrome;
Angelman syndrome)

Whole genome NIPT

Identifies deletions or duplications 7Mb or greater across
the entire genome, including aneuploidy for all 23
chromosomes and select copy number variants
previously described for NIPT+ common microdeletions

NIPT for select single gene
disorders (NIPT+ SGD)

Identifies de novo or paternally inherited mutations in the
following genes: BRAF, CBL, CDKL5, CHD7, COL1A1,
COL1A2, FGFR2, FGFR3, HDAC8, HRAS, JAG1, KRAS,
MAP2K1, MAP2K2, MECP2, NIPBL, NRAS, NSD1,
PTPN11, RAD21, RAF1, RIT1, SHOC2, SMC1A, SMC3,
SOS1, SOS2, SYNGAP1, TSC1, and TSC2

For each genetic condition, a test was selected if it had the potential to detect the
genetic aberration. When individuals had more than one identified genetic aberration,
only the one that explained the phenotype was used for determination of potential
diagnostic yield of prenatal testing.
Patient results were classified as negative or positive. Positive results were
further broken down into benign, possible, and causative Individuals with a possible
classification had a finding that could potentially explain their phenotype, but at the time
of data collection there was not a decision or resolution of the uncertainty. These
findings included variants of uncertain significance (VUS) in genes associated with the
phenotype or in candidate genes, CNVs identified in individuals with similar findings or
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normal phenotype, and likely diagnoses that needed further clinical correlation that could
not be evaluated as the patient was lost to follow up.
When an individual had a positive finding or findings that did not explain their
phenotype, they were included when determining the yield of that particular test in order
to reflect the true positive rate for that test, but the individual was not counted as having
a pathogenic variant causative of their structural abnormalities (causative genetic
aberration).

Calculating Diagnostic Yield
To calculate the diagnostic yield for a test for causative genetic aberrations, we
first calculated the number of patients in our dataset whose genetic aberration could
have potentially been identified by that test (NID). This was done by dividing the number
of patients with a causative genetic aberration that could have potentially been identified
by the test (NPOT) by the sum of the number of patients in our dataset that had any
causative genetic aberration identified (NCAU) and those that only had a negative, benign
or uncertain findings on appropriate testing (NNEG). Appropriate testing was defined as
the same test performed on the patient or a different test that would have been able to
identify the same aberration.
The NID was then multiplied by the detection rate of the test (DRT). For the
screening tests, the DRT was the sum of previously reported detection rates [11-14, 26,
27] of all the conditions that could have been identified by the test (Table 2), after taking
into account the prevalence of that condition in our study cohort in order to account for
the varying detection rates by condition for a particular test. Of note, the detection rate
for triploidy was determined using two publications [19, 21], as well as the consideration
of different rates of detection based on the origin of the extra genetic material.
Considering 85% of triploid pregnancies are diandric and 15% are digynic, the detection
rate for triploid pregnancy was estimated to be 97.8% using appropriate and available
7

screening methods (0.85*99%+0.15*91%=97.8%). For the diagnostic tests, the DRT
were assumed to be 100%. Therefore, our formula for calculating the diagnostic yield
(DY) for a test was as follows:
𝐷𝑌 =

𝑁𝑃𝑂𝑇
𝑥 𝐷𝑅𝑇
𝑁𝐶𝐴𝑈 + 𝑁𝑁𝐸𝐺

To determine the potential yield of testing, including individuals with benign
findings, the same procedure was followed, except instead of calculating NPOT, we
calculated NALL. NALL is the number of patients with a genetic aberration that could have
potentially been identified by the test (NALL).
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Table 2: Detection rates for prenatal screening tests by condition
Condition
Detection Rate
Aneuploidies
Trisomy 21
99.7% (99.1 – 99.9%)
Trisomy 18
97.9% (94.9 – 99.1%)
Trisomy 13
99.0% (65.8 – 100%)
Triploidy
97.80%
Monosomy X (45, X)
95.8% (70.3 - 99.5%)
Other SCA
100% (83.6 – 100%)
Copy Number Variants
22q11.2 deletion (DiGeorge) syndrome
53.9% (28-91%)
11q- (Jacobsen syndrome)
86.7% (57-99%)
5p- (Cri-du-Chat)
83.1% (48-96%)
8q24.1- (Langer-Giedion syndrome)
97.2% (80-99%)
1p36 deletion syndrome
50.7% (13-81%)
4p- (Wolf-Hirschhorn syndrome)
72.9% (37-91%)
15q- (Prader-Willi syndrome; Angelman syndrome)
59.2% (16-74%)
Whole Genome (>7 Mb)
95.9% (61-99%)
Single Gene Disorders
BRAF
96%
CBL
86%
CDKL5
84%
CHD7
91%
COL1A1
92%
COL1A2
92%
FGFR2
96%
FGFR3
96%
HDAC8
66%
HRAS
92%
JAG1
79%
KRAS
96%
MAP2K1
96%
MAP2K2
96%
MECP2
78%
NIPBL
94%
NRAS
96%
NSD1
87%
PTPN11
96%
RAD21
43%
RAF1
96%
RIT1
96%
SHOC2
96%
SMC1A
96%
SMC3
96%
SOS1
96%
SOS2
96%
SYNGAP1
89%
TSC1
96%
TSC2
82%

Source
[11]
[11]
[11]
[19, 21]
[11]
[11]
[14]
[14]
[14]
[14]
[14]
[14]
[14]
[14]
[12]
[12]
[12]
[12]
[12]
[12]
[12]
[12]
[12]
[12]
[12]
[12]
[12]
[12]
[12]
[12]
[12]
[12]
[12]
[12]
[12]
[12]
[12]
[12]
[12]
[12]
[12]
[12]
[12]
[12]
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Statistical Analysis
All data was analyzed using Stata (v13.1, College Station, TX). The categorical
variables were reported as frequencies with percentages. Comparisons between
categorical variables were performed using contingency tests (chi-square or Fisher
exact). The diagnostic yields were described as proportions with 95% confidence
intervals (CI) that were calculated as described by Wilson et al. [28]. These proportions
were compared between groups using a two-sample proportion test. Statistical
significance was assumed at a Type I error rate of 5%.

Results
Study Cohort
There were 931 records in the database maintained by the Medical Genetics
Department at the University of Texas McGovern Medical School during the study
period. Of these 931 subjects, 140 were excluded for not having a structural abnormality
potentially detectable by ultrasound. Of the 791 remaining subjects, 100 individuals did
not undergo genetic testing and were thus excluded from further analysis. There were a
range of reasons for not pursuing genetic testing, including denial by insurance, loss to
follow up, parental denial, lack of concern for a genetic condition, and in some cases, no
results were available despite the indication that a patient underwent testing. This left
691 study that met inclusion criteria (Figure 1)
An etiology for structural abnormalities was identified for 323 individuals in our
population with structural abnormalities, of which 222 individuals had an identified
genetic condition presumed to cause their structural abnormalities (Figure 2).
Additionally, twenty six individuals were given a clinical diagnosis (Table 3).

10

Figure 1: Breakdown of study cohort by testing and genetic aberration type
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Figure 2: Etiology of structural abnormalities
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Table 3: Clinical Diagnoses
Adams Oliver syndrome
Adrenal insufficiency
Beckwith-Wiedemann syndrome
Blue rubber bleb nevus syndrome (with rectal prolapse)
Campomelic dysplasia
Early infantile epileptic encephalopathy, type 5 (SPTAN1 mutation)
Epidermolysis Bullosa
GLUT1 deficiency
Infantile cortical hyperostosis (Caffey's disease)
Kniest chondrodystrophy
Metaphyseal dysplasia
Non-syndromic autosomal dominant polydactyly (x2)
Oculo-Auriculo-Vertebral spectrum
Opitz GBBB syndrome type 2
Osteogenesis imperfecta
Popliteal Ptyergium Syndrome
Proximal focal femoral deficiency (PFFD)
Prune-Belly syndrome
Pseudohypoaldosteronism type 2
Septo optic dysplasia (x2)
Spondylothoracic dysostosis
Thanatophoric dysplasia (x2)
Tuberous sclerosis complex (TSC)

Of the 691 patients that underwent genetic testing, 270 (39.1%) had a negative
result and 421 (60.9%) had a positive result. Of those with a positive result, 222 (52.7%)
were pathogenic and attributed to the phenotype of the patient. There were 151 (35.9%)
patients with one or more benign findings on genetic testing and 48 (11.4%) patients
with one or more uncertain results (such as a variant of uncertain significance in one or
more genes that could be related to phenotype), which were classified as “possible”
(Figure 1). There were 23 (5.5%) patients with a clinically significant finding presumably
unrelated to the structural abnormality on genetic testing (Table 4).
13

Table 4: Non-causative clinically relevant findings
Klinefelter syndrome
(x3 individuals; One mosaic individual)
Hereditary Breast and Ovarian Cancer Syndrome (HBOC)
(x2: One patient had a deletion including BRCA2; the other had a point mutation in BRCA2)
Disorder of Sexual Development /Discordant genitalia
(x2: one patient 46, XX with male genitalia; one patient 46, XY with female genitalia)
48, XXYY syndrome
COL3A1 pathogenic variant, Vascular EDS (type IV EDS)
Mitochondrial disease of tRNA Ser (MELAS due to MT-TS1 mutation)
Biallelic HADB mutations (mitochondrial trifunctional protein deficiency)
Becker Muscular Dystrophy due to 0.145 Mb deletion at Xp21.1 encompassing dystrophin gene
Autosomal dominant polycystic kidney disease (ADPKD)
Axenfield-Rieger syndrome type 3
SPTAN1 mutation, Early infantile epileptic encephalopathy, type 5
Factor VIII deficiency
von Willebrand disease (from other workup)
Copy number loss at 1p31.1 (that father also has) associated with dilated cardiomyopathy
Alpha thalassemia trait
Additional SHOX gene due to gain at Xp22.33
Triple X (47, XXX)
9.399 Mb deletion of Xq27, increasing risk for developmental delay

In patients without an identified pathogenic mutation to explain their structural
abnormalities and no other determined etiology, only 10.9% had comprehensive testing
(CMA and WES). A majority of the patients (89.1%) at least underwent a CMA, with only
12.2% undergoing WES.

Potential Diagnostic Yield
The potential yield for each test was broken down in the following ways: first, the
potential yield was calculated based on the number of individuals with a genetic
aberration identifiable by the test, including causative and benign findings. Second, the
diagnostic yield was refined for pathogenic variants that were described as causative of
an individual’s structural abnormalities.
14

When refined to pathogenic variants, CMA had the highest potential diagnostic
yield of all the available prenatal testing and screening options included in this study
[26.8% (95% CI: 23.5 -30.3)], followed by whole genome NIPT [21.2% (95% CI: 18.4 –
24.2)] karyotype [20.8% (95% CI: 17.8 – 24.0)], NIPT+CNVs [17.9% (95% CI: 15.3 20.9)], FISH [16.1% (95% CI: 13.5 - 19.1)], NIPT+ SCA [15.9% (95% CI: 13.4 - 18.9)],
WES [15.1% (95% CI: 11.3 - 19.7)], NIPT [13.7% (95% CI: 11.3 - 16.6)], Methylation
studies [2.4% (95% CI: 1.1 - 5.1)], NIPT+ SGD [2.3% (95% CI: 1.1 - 4.7)] and triplet
repeat analysis [1.3% (95% CI: 0.4 - 3.8)], (Table 5, Figure 3).
In addition to having the highest diagnostic yield, CMA was also significantly
more likely to identify a non-causative aberration compared to all other tests (p <0.001)
(Table 6), while WES was significantly more likely to identify a non-causative aberration
compared to all other testing options except CMA (p= 0.013). Almost half (43%) of the
findings identified by CMA were non-causative aberrations and 16% of the aberrations
identified by WES were non-causative, compared to the 0-6% non-causative findings
identified on all other tests.

15

Table 5: Potential diagnostic yield of prenatal testing for entire cohort
All Findings
Test
Denominator
DRT*
NALL ꝉ ꝉ
DY**, % (95% CIꝉ )
Screening tests
NIPT ꝉ
NIPT+ SCA ꝉ
NIPT +CNV ꝉ
Whole genome NIPT
NIPT + SGDꝉ

Causative, Pathogenic Findings
NPOT ꝉ

ꝉ

DY**, % (95% CIꝉ )

658
658
655
655

0.994
0.989
0.911
0.918

91
111
134
157

13.7 (11.3 - 16.6)
16.7 (14.1 - 19.7)
18.6 (16.0 - 21.6)
22.0 (19.2 - 25.1)

91
106
129
151

13.7 (11.3 - 16.6)
15.9 (13.4 - 18.9)
17.9 (15.3 - 20.9)
21.2 (18.4 - 24.2)

279

0.914

7

2.3 (1.1 - 4.7)

7

2.3 (1.1 - 4.7)

Diagnostic tests
658
1
111
16.9 (14.2 - 19.9)
106
16.1 (13.5 - 19.1)
FISH ꝉ
Karyotype
655
1
145
22.1 (19.1 - 25.5)
136
20.8 (17.8 - 24.0)
ꝉ
639
1
323
50.5 (46.7 - 54.4)
171
26.8 (23.5 - 30.3)
CMA
ꝉ
279
1
50
17.9 (13.9 - 22.9)
42
15.1 (11.3 - 19.7)
WES
Methylation studies
250
1
6
2.4 (1.1 - 5.1)
6
2.4 (1.1 - 5.1)
Triplet repeat analysis
228
1
3
1.3 (0.4 - 3.8)
3
1.3 (0.4 - 3.8)
* DRT = Detection Rate of the test (For screening test: previously reported detection rate x prevalence of condition in cohort; For
diagnostic tests: assumed to be 100%)
ꝉꝉ
NALL = number of patients with a genetic aberration that could have potentially been identified by the test ; NPOT = number of
patients with a causative genetic aberration that could have potentially been identified by the test
** DY = Diagnostic yield, (Numerator/Denominator) x DR x 100
ꝉ
NIPT = Non-invasive prenatal test ; SCA= sex chromosome aneuploidy ; CNV = copy number variant ; SGD = single gene
disorder; FISH = Fluorescent in situ hybridization; CMA = chromosomal microarray ; WES = whole exome sequencing ; CI =
confidence interval
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Karyotype
CMA
WES
Methylation studies

<0.001

<0.001

0.222

0.001

<0.001

0.574

<0.001

<0.001

0.334

0.014

<0.001

0.921

0.022

<0.001

0.758

<0.001

<0.001

0.132

<0.001

0.385

0.184

<0.001

0.298

<0.001

<0.001

<0.001

0.018

0.859

0.018

0.031

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

0.940

0.406

0.028

<0.001

0.701

<0.001

<0.001

0.011

0.043

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

CMA

0.037

NIPT+ SGD

Repeat
analysis

FISH

Methylation
studies

NIPT +SGD

WES

Whole genome NIPT

Karyotype

NIPT+ CNV

FISH

NIPT+ SCA

0.261

Whole
genome NIPT

NIPT

NIPT+ CNV

NIPT+ SCA

Table 6: p-values of prenatal testing for entire cohort

0.376

Table 6: p-values of two-sample proportion test between the potential detection rates of each prenatal test among the entire study cohort.
Statistical significance was assumed at a Type I error rate of 5%. Values bolded indicate statistical significance.
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Figure 3: Potential diagnostic yield of prenatal testing options for entire cohort
The potential diagnostic yield of each prenatal testing option is depicted by the bar graph.
Darker bars indicate the potential yield of pathogenic mutations presumed causative of an
individual’s structural abnormalities. The light bars indicate the additional yield of noncausative findings, which include benign findings, uncertain findings, and clinically significant
findings presumed unrelated to the structural abnormalities. An asterisk (*) indicates a p-value
less than 0.05 in two proportion comparison between CMA and every other test for both
causative and non-causative aberrations potential yield.
Study Cohort: Isolated structural abnormality vs multiple structural abnormalities
Of the 791 individuals in the cohort who had one or more structural
abnormalities, 143 (18.1%) had an isolated abnormality and 648 (81.9%) had multiple
structural abnormalities (MSA) (two or more structural abnormalities). Of 143 the
individuals with an isolated structural abnormality, 115 (80.4%) underwent genetic
testing. Of these individuals 23 (20.0%) had a pathogenic result that explained their
phenotype (Figure 4).
Of the 642 individuals with MSA, 576 (88.9%) underwent genetic testing. This
was significantly greater than the 80.4% testing rate among individuals with an isolated
structural abnormality (p=0.0057). Of these individuals, 199 (34.4%) had pathogenic
results that explained their phenotype (Figure 5).
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Figure 4: Breakdown of isolated cohort by testing and type of genetic aberration
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Figure 5: Breakdown of MSA cohort by testing and type of genetic aberration
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Potential Diagnostic Yield:
The potential diagnostic yield for each test was broken down in the same manner
as for the entire cohort. In the isolated cohort, WES had the highest potential diagnostic
yield for causative aberrations 25.9% (95% CI: 13.2 - 44.7), followed by CMA 14.9%
(95% CI: 9.2 - 23.1), (Table 7, Table 8). In the MSA cohort, CMA had the highest
potential diagnostic yield of 29.0% (95% CI: 25.3 – 33.0), followed by whole genome
NIPT 23.2% (95% CI: 21.8 – 29.0).
In addition to having the highest diagnostic yield, CMA was also significantly
more likely to identify a non-causative aberration compared to all other tests (p <0.001).
WES was also significantly more likely to identify a non-causative aberration compared
to all other testing options except CMA (p = 0.001). Similar to the entire cohort, almost
half (45%) of the findings identified by CMA were non-causative aberrations and 19% of
the aberrations identified by WES were non-causative, compared to the 0-5% of noncausative findings identified by all other tests (Table 9, Table 10).
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Table 7: Potential diagnostic yield of prenatal testing in individuals with an isolated structural abnormality
Test
Screening tests
NIPT ꝉ
NIPT+ SCA ꝉ
NIPT +CNV ꝉ
Whole genome NIPT
NIPT + SGDꝉ
Diagnostic tests
FISH ꝉ
Karyotype

Denominator

DRT*

105
105
104
104
27

0.997

0.988
0.907
0.911
0.820

All Findings
DY**, % (95%
NALL ꝉꝉ
CIꝉ)
7
10
12
13
1

6.6 (3.3 – 13.1)
9.4 (5.2 – 16.7)
10.5 (6.7 – 19.1)
11.4 (7.5-20.2)
3.0 (0.7 - 18.3)

Causative, Pathogenic Findings
NPOT ꝉꝉ

DY**, % (95% CIꝉ)

7
9
11
12
1

6.6 (3.3 – 13.1)
8.5 (4.6 - 15.5)
9.6 (6.0 – 18.0)
10.5 (6.7 -19.1)
3.0 (0.7 - 18.3)

10.5 (6.0-17.8)
10
9.5 (5.3 – 16.6)
13.5 (8.2 - 21.3)
11
10.6 (6.0 – 16.6)
42.6 (33.4 –
101
1.000
43
15
14.9 (9.2 – 23.1)
CMA ꝉ
52.3)
27
1.000
7
25.9 (13.1 - 44.7)
7
25.9 (13.2 - 44.7)
WES ꝉ
Methylation studies
27
1.000
0
0.0 (0 - 0)
0
0.0 (0 - 0)
Triplet repeat analysis
23
1.000
1
4.3 (0.8 -21.0)
1
4.3 (0.8 – 21.0)
* DRT = Detection Rate of the test (For screening test: previously reported detection rate x prevalence of condition in cohort; For
diagnostic tests: assumed to be 100%)
ꝉꝉ
NALL = number of patients with a genetic aberration that could have potentially been identified by the test ; NPOT = number of
patients with a causative genetic aberration that could have potentially been identified by the test
** DY = Diagnostic yield, (Numerator/Denominator) x DR x 100
ꝉ
NIPT = Non-invasive prenatal test ; SCA= sex chromosome aneuploidy ; CNV = copy number variant ; SGD = single gene
disorder; FISH = Fluorescent in situ hybridization; CMA = chromosomal microarray ; WES = whole exome sequencing ; CI =
confidence interval
105
104

1.000
1.000

11
14
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Methylation studies

Repeat
analysis

WES

Methylation
studies

CMA

WES

Karyotype

CMA

FISH

Karyotype

NIPT + SGD

FISH

Whole genome NIPT

NIPT+ SGD

NIPT+CNV

Whole
genome
NIPT

NIPT+SCA

NIPT+ CNV

NIPT

NIPT+ SCA

Table 8: p-values of prenatal testing in individuals with an isolated structural abnormality

0.602

0.427

0.313

0.478

0.440

0.302

0.054

0.004

0.170

0.678

0.782

0.622

0.329

0.800

0.605

0.152

0.013

0.117

0.495

0.829

0.266

0.980

0.811

0.247

0.025

0.094

0.413

0.224

0.810

0.981

0.344

0.038

0.079

0.356

0.271

0.220

0.096

0.017

0.365

0.806

0.791

0.236

0.023

0.096

0.420

0.356

0.040

0.077

0.350

0.179

0.033

0.172

0.005

0.038
0.277

Table 8: p-values of two-sample proportion test between the potential detection rates of each prenatal test among the isolated study
cohort. Statistical significance was assumed at a Type I error rate of 5%. Values bolded indicate statistical significance.
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Table 9: Potential diagnostic yield of prenatal testing in individuals with MSA
All Findings
Test
Denominator
DRT*
NALL ꝉꝉ
DY**, % (95% CIꝉ)

Causative Findings
NPOT ꝉꝉ

DY**, % (95% CIꝉ)

Screening tests
553
0.994
84
84
NIPT ꝉ
15.1 (12.4 - 18.4)
15.1 (12.4 - 18.4)
ꝉ
553
0.989
101
97
NIPT+ SCA
18.1 (15.3 - 21.7)
17.54(14.6 - 21.0)
551
0.911
122
118
NIPT +CNV ꝉ
20.2 (18.9 - 25.9)
19.5 (18.2 - 25.0)
551
Whole genome NIPT
0.919
144
139
24.0 (22.6 - 30.0)
23.2 (21.8 - 29.0)
ꝉ
252
0.930
6
5
NIPT + SGD
2.2 (1.1 -5.1)
2.2 (1.1 -5.1)
Diagnostic tests
553
1
100
96
FISH ꝉ
18.1 (15.1 - 21.5)
17.4 (14.4 - 20.7)
551
Karyotype
1
131
125
23.8 (20.4 - 27.5)
22.7 (19.4 - 26.4)
ꝉ
538
1
808
156
CMA
52.0 (47.8 - 56.2)
29.0 (25.3 - 33.0)
252
1
43
35
WES ꝉ
17.1 (12.9 - 22.2)
13.9 (10.2 - 18.7)
223
Methylation studies
1
6
6
2.7 (1.2 - 5.7)
2.7 (1.2 - 5.7)
205
Triplet repeat analysis
1
2
2
1.0 (0.3 - 3.5)
1.0 (0.3 - 3.5)
* DRT = Detection Rate of the test (For screening test: previously reported detection rate x prevalence of condition in cohort; For
diagnostic tests: assumed to be 100%)
ꝉꝉ
NALL = number of patients with a genetic aberration that could have potentially been identified by the test ; NPOT = number of patients
with a causative genetic aberration that could have potentially been identified by the test
** DY = Diagnostic yield, (Numerator/Denominator) x DR x 100
ꝉ
NIPT = Non-invasive prenatal test ; SCA= sex chromosome aneuploidy ; CNV = copy number variant ; SGD = single gene disorder;
FISH = Fluorescent in situ hybridization; CMA = chromosomal microarray ; WES = whole exome sequencing ; CI = confidence interval
MSA = multiple structural abnormalities, two or more structural abnormalities
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FISH
Karyotype
CMA
WES

NIPT+ SGD

Whole genome
NIPT

0.053

0.001

<0.001

0.300

0.001

<0.001

0.656

<0.001

<0.001

0.368

0.016

<0.001

1.000

0.028

<0.001

0.213

<0.001

<0.001

0.134

<0.001

0.368

0.193

<0.001

0.054

<0.001

<0.001

<0.001

0.017

0.844

0.029

0.002

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

0.724

0.318

0.028

<0.001

0.213

<0.001

<0.001

<0.001

0.213

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

CMA

Repeat
analysis

NIPT+ SGD

Methylation
studies

Whole genome NIPT

WES

NIPT+ CNV

Karyotype

NIPT+ SCA

0.300

FISH

NIPT

NIPT+ CNV

NIPT+ SCA

Table 10: p-values of prenatal testing in individuals with MSA

Methylation studies

0.197

Table 10: p-values of two-sample proportion test between the potential detection rates of each prenatal test among the MSA study
cohort. Statistical significance was assumed at a Type I error rate of 5%. Values bolded indicate statistical significance.
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Comparison of isolated cohort to MSA cohort
The potential diagnostic yield was significantly higher for all test types in
individuals with MSA compared to individuals with an isolated strucutral abnormality
except NIPT+SGD, WES, methylation studies and repeat analysis (Figure 6). For these
tests, there were no significant differences in diagnostic yield based on isolated or
multiple structural abnormalities.

Figure 6: Potential diagnostic yield of prenatal testing options in isolated and MSA
cohorts
The potential yield of each prenatal testing option is depicted by the bars. The light grey bars
indicate the yield of a test in the isolated structural abnormalities cohort and the dark grey bars
indicate the same in the multiple structural abnormalities cohort. Listed p-values are significant
differences in the potential yield of testing modalities between the MSA and isolated cohorts.
Those not listed did not reach significance.
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Discussion
Chromosome Abnormalities
Of the 222 patients with a causative genetic aberration identified in our study,
164 (74%) were diagnosed with a chromosome abnormality or microdeletion or
duplication (aneuploidy, unbalanced translocations, or copy number variants). Therefore,
CMA had the highest potential diagnostic yield across the entire cohort compared to
other prenatal screening and testing options. CMA also had a significantly higher
diagnostic yield among individuals with MSA compared to an isolated structural
abnormality (p = 0.003), indicating a high incidence of chromosome abnormalities in the
presence of MSA. This is consistent with previous studies comparing CMA and
karyotype, studies comparing CMA to NIPT, and studies comparing CMA in pregnancies
with isolated vs. multiple anomalies [4, 17, 24].
Not surprisingly, the potential diagnostic yield of CMA was significantly greater
than all NIPT screening options, including whole genome NIPT (p =0.018), further
supporting the recommendation to use diagnostic testing over screening methods after
identification of an ultrasound abnormality [2, 18]. Assuming data on detection rates for
whole genome are accurate, there is potentially a loss of 5.6% of prenatal diagnoses if
whole genome NIPT is used over CMA after identification of one or more structural
abnormalities. This is important to discuss when reviewing test options, as the difference
in diagnostic yield might influence whether a patient to chooses an invasive procedure
over a screening procedure.
Due to the high rate of chromosome abnormalities and microdeletions and
microduplications detected in our cohort, whole genome NIPT had the second highest
potential yield in this study and karyotype had the third highest potential yield, but these
were not significantly different from each other (p=0.845). From this data, one could
extrapolate that whole genome NIPT provides an overall yield comparable to a
karyotype. However, until sufficient data is published in peer reviewed journals
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supporting high sensitivity and specificity claimed in the current literature for whole
genome NIPT one may wish to proceed with caution at equivocating the two [13].

Single gene disorders
Forty-two patients were found to have a single gene disorder in our cohort
(18.9%) that could be detected by a sequencing test, such as whole exome sequencing,
but would not be found on a CMA or whole genome NIPT. The potential diagnostic yield
of prenatal WES across our isolated and MSA, corresponds with the previously reported
prenatal WES yield of 6.2-80% [5-8]. The predicted diagnostic yield from this study
could potentially be lower in practice in a prenatal population, as the patients were
evaluated after delivery and thus could have had additional clinical indications to suggest
a single gene disorder that would not have been detected on a prenatal ultrasound.
WES findings were detected in 35 different genes, of which only 7 could have
been screened by clinically available NIPT+SGD. This was reflected in the significant
differences in potential diagnostic yield for prenatal WES and NIPT+SGD in both the
isolated structural abnormality cohort [25.9% vs 3.0%], and MSA cohort [13.9% vs
2.2%]. While NIPT+SGD provides another avenue to identify individuals with a single
gene disorder, the use of this test is limited to the specific genes on the panel and
conditions that are de novo or paternally inherited. In addition, the only data available on
this clinically available test is a single white paper and the detection rates quoted range
from 43-99% [16]. These are important limitations to stress during pre-test counseling.
Due to the challenge of obtaining insurance coverage for prenatal whole exome
sequencing, we sought to identify sequencing panels that could identify the genetic
aberration in our single gene diagnosis category. We were able to identify available
prenatal sequencing panels for 22 of the 35 different genes, which could have potentially
provided a diagnosis for 29 out of the 42 (69.0%) individuals with an identified single
gene disorder. The remaining 31% of these individuals could only have been identified
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by prenatal WES. This demonstrates the utility of prenatal WES and the need for
insurance coverage of prenatal WES after identification of one or more structural
abnormalities on ultrasound.

Incidental and Uncertain Findings
In addition to the highest potential diagnostic yield, CMA had the highest rate of
benign or uncertain results compared to all screening counterparts and other diagnostic
tests (p<0.001). This is an important component of pre-test counseling to ensure there is
a full consent to the testing type and the possibility of identifying a result that is either not
causative of the identified structural abnormalities, an incidental finding, or variant of
uncertain significance that could potentially provide an answer in the future or not.
WES had the second highest rate of benign or uncertain findings compared to
other screening and diagnostic tests (p = 0.013). The higher rate of incidental findings on
WES in our study cohort might be lower in a prenatal population, as the reporting is
slightly different. Prenatal WES reports are typically focused on genes known to cause
abnormalities noted in the clinical indication. Reports can include variants of uncertain
significance and secondary findings. Our study cohort had 8 individuals with a finding
potentially identifiable on prenatal WES that were not causative aberrations. Prenatal
reporting of these findings would depend upon the performing laboratory and patient
preferences.
Uncertain or incidental findings may also be identified through NIPT but due to
variable reporting practices by NIPT laboratories we are unable to quantify how often
these incidental findings may be detected and reported by a screening test.

Utilization of diagnostic yield in clinical settings
Discussions about prenatal testing options after the identification of one or more
structural abnormalities should include a discussion of the risks, benefits and limitations
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of genetic testing to allow for well-informed and autonomous patient decision-making.
The diagnostic yields described in this study should be used as a baseline for this pretest counseling. There are many other factors that should be considered in addition to
potential diagnostic yield, including the differential diagnosis, patient desire for
information, cost of testing/insurance coverage compared to the increase in yield, the
potential for uncertain, incidental, or secondary findings, and the positive predictive value
of testing. In addition, clinicians should also integrate relevant information such age,
family history, and abnormalities identified to help direct testing recommendations.

Strengths and Limitations
Our study included a large population of infants who were seen by board certified
medical geneticists in a large tertiary care, academic medical center. This setting
allowed for a large study cohort of patients that underwent accurate postnatal
assessments, but as in any retrospective chart review, ours was limited by information
recorded in the electronic medical record. The patients in this study were first seen by
the medical genetics team between January 2014 and December 2017, which should
have allowed adequate time for full genetic workup by the time of data collection in fall
2018.
However, not every individual received the recommended workup due to
insurance denials or loss to follow up. Furthermore, testing strategies utilized by
healthcare providers are influenced by the clinical presentation, family history, cost
considerations (including insurance), patient follow-up, and results of any other testing
done. Since our data on the yield of the tests relies on which tests were or were not
performed in our cohort, factors that influence testing might act as potential confounders
and/or effect modifiers in our analysis. This is highlighted by the 77% (n=306, 95% CI:
73.10 – 81.31) who did not have a comprehensive workup (CMA & WES)
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Additionally, the diagnostic yield experienced in a prenatal testing setting may not
be equivalent due to postnatal ascertainment bias. Structural abnormalities were
included in this study if they had the potential to be detected by prenatal ultrasound. We
did not confirm that all structural abnormalities were in fact detected prenatally. Some
structural abnormalities may not be detected on routine ultrasound or by all ultrasound
centers and thus the classification of a patients as having an isolated or multiple
structural abnormalities may differ between institutions, and thus the potential diagnostic
yield of testing will vary as a function of the skills of the sonographers and the nature of
the defects.
In order to evaluate diagnostic yields reflective of screening tests, prenatal
screening test sensitivities were determined using current literature, which leads to some
limitations. For some of the conditions on these screens, such as Down syndrome,
robust data exists from which we were able to obtain well supported detection rates. For
conditions that have been added to screening tests more recently, such as microdeletion
syndromes and select autosomal dominant single gene disorders, data regarding the
sensitivity of testing is not as widely available nor is it nearly as well established.
Despite these limitations, this study includes the most prenatal screening and
diagnostic options available in clinical settings than any other previous study, providing a
more robust look at the potential diagnostic yield of all prenatal testing options available.

Conclusions
The data presented here provide further evidence that CMA has the highest
potential diagnostic yield among all current prenatal testing options after identification of
one or more structural abnormalities on ultrasound. Additionally, CMA also had the
highest rate of non-causative (benign, uncertain, or incidental) results. As expected,
screening tests had a lower potential yield compared to CMA. Expanded NIPT
(NIPT+CNVs and whole genome NIPT) had a higher potential yield than traditional NIPT
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and whole genome NIPT had a comparable yield as a karyotype. While interesting, it is
important to consider the limited data on expanded NIPT and how this might affect study
results and post-test counseling regarding screening results. When deciding which
testing options to pursue, patients should be counseled about the differences in potential
yield of testing among diagnostic and screening tests, and be informed of the potential of
obtaining a result that is uncertain or considered incidental. Further investigation into the
potential yield of expanded NIPT panels and prenatal WES should be explored.
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Appendix
Supplemental Table 1: Pathogenic findings presumed causative of structural abnormalities
Aneuploidies

n

Iso

MSA

Mos

8
2
2
1
3
1
11
68
2
98

2

1
2
2

6
1
8

6
2
2
1
3
1
11
62
1
89

Unbalanced translocation/chromosome rearrangements

n

Iso

MSA

Mos

Monosomy X (Turner syndrome)
Monosomy X and isodicentric Y
Tetrasomy isochromosome 12p (Pallister-Killian)
Trisomy 13
Trisomy 18
Trisomy 21

1
1
1
1
1
3
1
1

Monosomy X (Turner syndrome)
Monosomy X (ring X)
Monosomy X/ 46, XY
Triploidy
Trisomy 13
Trisomy 16
Trisomy 18
Trisomy 21
49, XXXXY
Total

1
1
1
1
1
3
1
1

Complex chromosome 8 rearrangement

1

1

Derivative chromosome 12 with terminal duplication
1q deletion and 9p duplication
4q terminal deletion and 8q terminal duplication

1
1
1

1
1
1

1

1
1

1

FISH/Karyotype/CMA result

45, X ; 45,X/46, XX
45, X/46, X, +r
45, X/ 46, XY
69, XXX
47, XX, +13 (47, XY, +13)
47, XY, +16 /46, XY
47, XX, +18 (47, XY, +18)
47, XX, +21 (47, XY, +21)
49, XXXXY

Karyotype/CMA result

46, X, der(X)t(X;7)(q24;q22)
45,X[26]/46,X, psu idic(Y)(q11.23)[4]
Tetrasomy 12p
46, XY, +13, der(13;14)(q10;q10)
46, XX, der(3)t(3;18)(p26.1;q11.2)
46, XX, +21, der(21;21)(q10;q10)
46, XY, +21 der(21;21)(q10;q10)
46, XX, +21, der(13;21)(q10;q10)
8p23.3p23.1(194617-8403434)x1, 8p23.1p12(12580104-33119221)x3,
8q24.12q24.3(121831416-146294241)x3
12p13.33p13.32(189216-3454991)x1, 12p13.32p12.1(352331323666601)x3
9p duplication, 1q deletion
46,XX,der(4);t(4,8)(q35.2-24.3)
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5p deletion and 9p duplication
Partial trisomy 5p

1
1

1
1

5p15.33p15.2(113576-11410194)x1, 9p24.3p22.2(203861-18301446)x3
46, XX, add 5p15.2

5 and 12
Partial 7q duplication

1
1

1
1

9p deletion and 4q duplication
10q26.12 deletion and 3p26.3 duplication
1q32-q41 and q41;qter duplication, and 10q terminal
deletion
Total

1
1

1
1

Unbalanced translocation between chromosomes 5 and 12
partial 7q duplication
4q32.3q35.2(164780923-190791227)x3, 9p24.3p22.3(20745414746829)x1
46, XX, der(10)t(3;10)(p25.1;q26.12)
1q32-q41 duplication, 1q41;qter duplication, 10q terminal deletion

1
21

Copy Number Variants

n

1p31.1-31.2 interstitial deletion
1p34 deletion
1p36 deletion syndrome
1q43 deletion syndrome
2p23.3p25.1 deletion
2q22.1q33.2 deletion syndrome
3q deletion syndrome
3q26.32q29 duplication
4q31.3 deletion syndrome
7q11.23 deletion (Williams syndrome)
7q22.3 deletion
7q36.2 deletion
8q11.21q12.1 deletion
9q34.3 deletion (Kleefstra Syndrome)
13q12.3q13.2 deletion
14q32.31 deletion
15q11.2q13.3 deletion (Prader Willi syndrome)

1
1
2
3
1
1
1
1
2
1
1
1
1
1
1
1
1

1

1
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Iso

MSA

1

1
1
2
2
1

1
1
1
2
1
1
1
1
1
1
1
1

Mos

1

CMA result

Size (range)

1p31.1p32.1 interstitial deletion
1p34.1p32.3 deletion (45748571-54527813)
1p36.3 deletion
1q43q44 deletion
2p23.3p25.1 deletion
2q33.1q33.2 deletion (199710981-204484143)
3q deletion
3q26.31q29 duplication (174251329-197717518)
4q31.3 deletion
7q11.23 deletion (72744494-74142327)
7p22.3 deletion (1-2759647)
7q36.2 deletion (153584506-153647972)
8q11.23q12.1 deletion (54871180-58883606)
9q34.3 deletion (139876171-141213421)
13q12.3q13.2 deletion (28933097-35163380)
14q32.31 deletion
15q11.2q13.3 deletion

13.35 Mb
8.779 Mb
3.4-9.736 Mb
4.88-12.1 Mb
15.8 Mb
4.773 Mb
23.47 Mb
38-38.392 Mb
1.3 Mb
2.760 Mb
0.063 Mb
4.012 Mb
1.337 Mb
6.230 Mb
10.75 Mb
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15q21.2 deletion
15q26.2-q26.3 deletion
16p13.3 deletion
16q12.2 deletion
17p13.3 deletion (Miller-Dieker syndrome)
18q11.2 interstitial deletion
21q22.3 deletion
22q11.21 deletion syndrome (DiGeorge syndrome)
22q13.31q13.33 deletion (Phelan McDermid)
Xp11.4 deletion
Total

1
1
1
1
1
1
1
19
1
1
49

5

1
1
1
1
1
1
1
17
1
1
44

Iso

MSA

2

15q21.2q22.2 deletion (50833347-61673964)
15q26.2-q26.3 deletion (95462599-102354857)
16p13.3 deletion (3639643-4261338)
16q12.2q21 deletion (54514235-64397522)
17p13.3p13.2 deletion (1-5559951)
18q11.2 deletion
21q22.3 deletion (43619800-48157577)
22q11.21 deletion
22q13.31q13.33 deletion (47388907-51304566)
Xp11.4 deletion (41589371-41599075)

10.841 Mb
7.096 Mb
0.622 Mb
9.883 Mb
5.487 Mb
0.518 Mb
4.5 Mb
2.762 - 5.747 Mb
3.916 Mb
0.010 Mb

Single gene disorders

n

3-methylglutaconic aciduria type VII
Achondrogenesis type 2 or hypochondrogenesis
Adams-Oliver syndrome
Androgen insensitivity
Antley-Bixlar syndrome (POR deficiency)
ARX related disorder
Autosomal Recessive Polycystic Kidney Disease
(ARPKD)
Beckwith-Wiedemann Syndrome (BWS)
Brain-Lung-Thyroid Syndrome
BRAT1 syndrome (Rigiddty and multifocal seizure
syndrome, leathal neonatal)
Campomelic dysplasia

1
1
1
1
1
1

1
1
1
1
1
1

CLPB: c.[1156+1G>A] ; [1156+1G>A]
COL2A1: c.1587G>A (p.Gly513Ser)
NOTCH1: c.166C>T (p.R56*)
AR: c.2659A>G (p.M887V)
POR: c.859G>C (p.Ala287Pro)
ARX: c.1295_ 1317dup23 (p.A440fs)

1
1
1

1
1
1

PKHD1: c.[3761_3762delCCinsG] ; [5895dupA]
CDKN1C: c.189C>G (p.Tyr63*)
NKX2-1: c.390C>G (p.Y130X)

1
2

1
2

CHARGE syndrome

2

2

Congenital Adrenal Hyperplasia (CAH)

1

1

BRAT1: c.[1710delG] ; [566dupG]
SOX9:c.628_638dup11
SOX9: c.55delT
CHD7: c.779_780delCC (p.P260fs)
CHD7: c.3065_3066dupTT (p.A1023Lfs*20)
CYP21: In2G mutation and large gene conversion due to 30 kb deletion of
CYP21A1P and CYP21A2

Mos

Gene and coding change(s)
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Congenital diaphragmatic hernia and heart defects,
multiple 4
Cystic Fibrosis
Desbuquois dysplasia type 2
Dilated cardiomyopathy 1S
Heterotaxy syndrome due to NODAL mutation
Hypertrichotic osteochondrodysplasia (Cantu
syndrome)
Joubert syndrome type 10
Kabuki Syndrome
Kniest dysplasia
Mandibulofacial Dysostosis, Guion-Almedia Type
Marfan syndrome
Morquio Syndrome A (MPS 4)
Multiple Endocrine Neoplasia type 2 (MEN2)
Noonan syndrome
Osteogenesis Imperfecta type III
Pfeiffer syndrome type 3
Simpson-Golabi-Behmel syndrome
Stickler syndrome
TARP syndrome
Tuberous Sclerosis Complex (TSC)
X-Linked hydrocephalus
X-linked Spinal Muscular Atrophy
ZIC3 mutation
Total

1
2
1
1
1

1
2
1
1
1

1
1
1
1
1
2
2
1
1
1
1
1
1
1
1
1
1
1
1
42

1
1
1
1
1
2
1
1

1
1
1
1
1
1
1
1

1
1
1
1
7

NR2F2: c.103_109delGGCGCCC (p.Gly35ArgfsTer75)
CFTR: c.[1521_1523delCTT] ; [unknown] **+ sweat test
CFTR: c. [1521_1523delCTT]; [1288insTA]
XYLT1: c.[2560G>T] ; [2560G>T]
MYH7 : c.602T>C (p.I201T)
NODAL: c.778G>A (p.G260R)
ABCC9: c.1664T>C (p.F555S)
OFD1: c.2668C>T (p.R890X)
KMT2D: c.10938_10939delinsT (p.P3647fs)
COL2A1 pathogenic mutation
EFTUD2: c.702+1G>T
FBN1: c.3094T>C (p.Cys1032Arg)
FBN1: c.4188delA (p.Gly1397Valfs*16)
GALNS: c. [633+1G>C ]; [1558T>C] *sibs
RET: c.1144C>T (p.Gln382*)
PTPN11: c.854T>C (p.F285S)
HRAS: c.34G>A (p.G12S)
COL1A2: c.821G>A (p.Gly274Asp)
FGFR2: c.870G>T (Pro250Arg)
GPC3: c.760C>T (p.Arg254*)
COL2A1: c.1587G>A (p.Gly513Ser)
RBM10: c.1473_1474delGT (p.S492Dfs*25)
TSC2: c.2590C>T (p.Gln864X)
L1CAM: c.2014C>T (p.GLN672*)
UBA1: c.1731C>T (p.N577N)
ZIC3: c.75C>G (p.H25Q)

35

36

Methylation Disorders

n

Beckwith Wiedemann syndrome (BWS)
Beckwith-Wiedemann syndrome (BWS)
Russell Silver syndrome (RSS)
Prader Willi syndrome (PWS)
Total

3
1
1
1
6

0

Triplet Repeat Disorders

n

Iso

Congenital Myotonic Dystrophy (type 1)
Congenital Central Hypoventilation Syndrome
(CCHS)
Total

2
1
3

1
1

"Other" Disorders

n

Iso

Testicular Disorder of Sexual Development
Mosaic Trisomy 21 and Trisomy 18
Uniparental disomy of chromosome 20
Total

1
1
1
3

Iso

MSA

Mos

3
1
1
1
6
MSA

IC2 (LIT1) hypomethylation
Paternal UPD of 11p15
Loss of methylation at DMR1
Maternal UPD of 15q11.2-11.3

Mos

Gene, triplet repeat, number of repeats

DMPK: greater than 1500 CTG repeats

2

0

Methylation analysis

PHOX2B: 27 and 20 polyalanine repeats
2
MSA

1
1
1
3

Mos

1

Description of defect

46, XX (with male genitalia)
Mosaic Trisomy 21 [70%] and Trisomy 18 [30%]
Uniparental disomy of chromosome 20 (AOH of chromosome 20)

†

Iso = isolated structural abnormality; MSA = multiple structural abnormalities (more than 1); Mos = Mosaic, FISH = Fluorescent in situ hybridization;
CMA = chromosomal microarray
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Supplemental Table 2: Structural abnormalities included in study
n*
Isolated MSA*
Organ system
465
85
380
Cardiac
102
5
97
Central nervous system
57
3
54
Effusion
423
7
416
Face/ear
185
11
174
Gastrointestinal
89
4
85
Genital
180
13
167
Growth
138
2
136
Head shape
8
0
8
NT/nuchal fold/cystic hygroma
13
0
13
Placental
145
3
142
Prenatal
78
3
75
Renal
180
4
176
Skeletal
65
0
65
Spine
40
2
38
Thorax
41
0
41
Umbilical
24
1
23
Other
Total
2233
143
2090
n = number of individuals with a structural abnormality in specified
organ system.
MSA = multiple structural abnormalities
*not mutually exclusive and therefore do not add up to 791 and 647
respectively
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